- Home
- CRT vs TIL Comparison
CRT vs TIL Comparison
Compare CRT & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | TIL |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.9M | 52.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRT | TIL |
|---|---|---|
| Price | $12.76 | $7.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | ★ 29.2K | 9.2K |
| Earning Date | 04-14-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.29% | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.07 | $5.67 |
| 52 Week High | $13.15 | $21.98 |
Technical Indicators
Market Signals| Indicator | CRT | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 71.30 | 40.43 |
| Support Level | $10.18 | $6.91 |
| Resistance Level | N/A | $7.50 |
| Average True Range (ATR) | 0.49 | 0.22 |
| MACD | 0.19 | -0.06 |
| Stochastic Oscillator | 82.46 | 16.22 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.